{"schema_version":"1","generated_at":"2026-10-28T07:38:33.482Z","data_as_of":null,"url":"https://www.findmykol.com/kol/james-blachly","json_url":"https://www.findmykol.com/kol/james-blachly/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"james-blachly","name":"James Blachly","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"The Ohio State University Comprehensive Cancer Center","institution_url":"https://www.findmykol.com/institution/the-ohio-state-university","city":"Columbus","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1679779284","orcid":"0000-0002-4275-5562","openalex":"A5080781659"},"summary":"James Blachly is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 462 publications with 6,535 citations (h-index 43); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":462,"cited_by_count":6535,"h_index":43,"latest_activity_year":2025,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT03724084","title":"Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement","phase":"PHASE1/PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT03724084","trial_url":"https://www.findmykol.com/trial/NCT03724084"},{"nct":"NCT02285244","title":"Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation","phase":"PHASE2","status":"WITHDRAWN","role":"Overall official","sponsor":"James Blachly","source_url":"https://clinicaltrials.gov/study/NCT02285244","trial_url":"https://www.findmykol.com/trial/NCT02285244"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":null},"rows_total":8,"shown":3,"withheld":5,"rows":[{"payer":"Syndax Pharmaceuticals, Inc.","program_year":2025,"amount_usd":9180.03,"payment_count":12,"source_url":"https://openpaymentsdata.cms.gov/search?query=1679779284"},{"payer":"Astellas Pharma US Inc","program_year":2024,"amount_usd":153.98,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1679779284"},{"payer":"AbbVie Inc.","program_year":2023,"amount_usd":6983.54,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1679779284"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1679779284","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":88.1,"classes_total":6,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":30.1,"drugs":[{"name":"Sprycel","share_pct":25},{"name":"Imatinib Mesylate","share_pct":23.5},{"name":"Bosulif","share_pct":19.1},{"name":"Tasigna","share_pct":16.2},{"name":"Jakafi","share_pct":16.2}],"max_beneficiaries":null},{"class":"BCL-2 Inhibitor","setting":"prescribed","share_pct":27.4,"drugs":[{"name":"Venclexta","share_pct":100}],"max_beneficiaries":17}]},{"area":"Dermatology","share_pct":6.6,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":6.6,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":5.3,"classes_total":1,"classes":[{"class":"Azole Antifungal","setting":"prescribed","share_pct":5.3,"drugs":[{"name":"Fluconazole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025028357","status":"verified"},{"title":"Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.00826","status":"verified"},{"title":"A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies","year":2024,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-24-0028","status":"verified"},{"title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2023021959","status":"verified"},{"title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","year":2023,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-023-01846-8","status":"verified"}],"source":"works"},"contact":{"address_1":"460 W 10TH AVE","city":"Columbus","state":"OH","zip":"432101240","phone":"614-293-3196","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1679779284","source":"identity"},"similar":[{"name":"Gregory Otterson","slug":"gregory-otterson","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gregory-otterson","json_url":"https://www.findmykol.com/kol/gregory-otterson/profile.json"},{"name":"Raphael Pollock","slug":"raphael-pollock","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/raphael-pollock","json_url":"https://www.findmykol.com/kol/raphael-pollock/profile.json"},{"name":"Steven Clinton","slug":"steven-clinton","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/steven-clinton","json_url":"https://www.findmykol.com/kol/steven-clinton/profile.json"},{"name":"Claire Verschraegen","slug":"claire-verschraegen","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/claire-verschraegen","json_url":"https://www.findmykol.com/kol/claire-verschraegen/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":5,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-02-22","provider_certified":"2021-02-22","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}